Malignant astrocytoma is a serious brain tumor that requires prompt attention and a carefully planned approach combining surgery, radiation, and chemotherapy, with new treatment strategies now being explored in clinical trials around the world.

How Treatment Decisions Are Made for Malignant Astrocytoma

When someone is diagnosed with malignant astrocytoma, a type of cancerous brain tumor, the first question that arises is about treatment options. The main goal of treating malignant astrocytoma is to control the growth of the tumor, reduce symptoms such as headaches or seizures, and help patients live longer with a better quality of life. Treatment decisions depend on many factors including the tumor’s grade, its location in the brain, the patient’s age and overall health, and whether the tumor has certain genetic changes.^[1][2]

There are established treatment approaches that medical societies around the world recommend based on years of research and patient care. At the same time, scientists and doctors are continuously studying new therapies in clinical trials, which are carefully controlled research studies that test whether new treatments are safe and effective. These trials offer hope for better outcomes in the future and sometimes provide access to cutting-edge therapies not yet widely available.^[3]

Malignant astrocytomas are classified into different grades based on how aggressive they are. Grade 3 astrocytomas, also called anaplastic astrocytomas, grow more quickly and invade surrounding brain tissue. Grade 4 astrocytomas, known as glioblastomas, are the most aggressive and fast-growing type. The grade of the tumor significantly influences which treatments doctors recommend and in what order they should be given.^[3][13]

Treatment usually involves a team of specialists including a brain surgeon (neurosurgeon), a radiation doctor (radiation oncologist), and a cancer medicine specialist (medical oncologist or neuro-oncologist). This team works together to create a personalized treatment plan. The approach is rarely just one treatment alone—most patients receive a combination of surgery, radiation therapy, and chemotherapy to achieve the best possible results.^[12][14]

Standard Treatment Approaches for Malignant Astrocytoma

Surgery as the First Step

Surgery is almost always the first treatment for malignant astrocytoma when the tumor is located in a part of the brain that can be reached safely. The main purpose of surgery is to remove as much of the tumor as possible without damaging important brain areas that control speech, movement, or other essential functions. Even though it is impossible to remove every single cancer cell because these tumors spread into surrounding brain tissue, removing the bulk of the tumor can reduce pressure in the brain, relieve symptoms, and make other treatments more effective.^[12][14]

Studies have shown that removing more of the tumor leads to better survival rates. For example, patients with glioblastoma who have more than 98% of the visible tumor removed tend to live longer than those with less complete surgery. Brain surgeons use advanced techniques such as functional MRI (a special type of brain scan) and intraoperative mapping to identify critical brain regions before and during surgery. Some surgeons also use fluorescent dyes like 5-ALA (aminolevulinic acid), which makes tumor cells glow under special light in the operating room, helping to see tumor edges more clearly.^[14][16]

In cases where the tumor is located in a difficult-to-reach or highly sensitive area of the brain, complete removal might not be possible. In such situations, doctors may perform a biopsy—a procedure to take a small tissue sample for diagnosis—and then proceed with radiation and chemotherapy without extensive surgery.^[12]

Radiation Therapy

After surgery, radiation therapy is typically the next step for patients with malignant astrocytoma. Radiation therapy uses high-energy X-rays or other types of radiation to destroy cancer cells that remain in the brain after surgery. Because malignant astrocytomas spread into normal brain tissue in a way that makes complete surgical removal impossible, radiation is essential to target these remaining cells.^[12][15]

Radiation is usually given five days a week for about six weeks. Each session is short and painless, though patients may experience side effects over time. Common side effects include fatigue (feeling very tired), hair loss in the treated area, scalp irritation, and sometimes nausea. Some patients may also develop cognitive changes, such as memory problems or difficulty concentrating, especially if large areas of the brain receive radiation. These effects can appear weeks to months after treatment ends.^[12]

Doctors carefully plan radiation treatment using detailed brain scans to focus the radiation beams on the tumor area while sparing as much healthy brain tissue as possible. Newer techniques like intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery allow for more precise targeting.^[14]

Chemotherapy

Chemotherapy involves using drugs to kill cancer cells or stop them from growing. For malignant astrocytoma, chemotherapy is almost always part of the treatment plan, especially for grade 3 and grade 4 tumors. The most commonly used chemotherapy drug for these tumors is temozolomide (often called by its brand name Temodar). This drug is taken as a pill, making it more convenient than intravenous chemotherapy.^[14][15]

Temozolomide works by damaging the DNA inside cancer cells, which prevents them from dividing and growing. It is typically given during radiation therapy (usually daily) and then continued for several months afterward in higher doses for five days out of every 28-day cycle. This approach has been shown to improve survival in patients with glioblastoma compared to radiation alone.^[14]

Side effects of temozolomide can include nausea, vomiting, fatigue, constipation, and lowered blood cell counts, which can increase the risk of infection or bleeding. Regular blood tests are needed to monitor these effects. Some patients also experience hair thinning, though complete hair loss is uncommon with this drug. Most side effects are manageable with supportive medications and dose adjustments.^[14]

For certain patients with genetic changes in their tumors, such as IDH mutations or loss of a chromosome marker called 1p/19q, combination chemotherapy with drugs like lomustine or a combination of procarbazine, lomustine, and vincristine (called PCV) may be recommended. These combinations have shown benefit in specific tumor types during clinical studies.^[15]

Additional Medications

Many patients with malignant astrocytoma experience seizures, which occur when abnormal electrical activity in the brain causes temporary changes in behavior, movements, or consciousness. Doctors often prescribe anticonvulsant or anti-seizure medications such as levetiracetam, phenytoin, or valproic acid to prevent or control seizures. These medications need to be taken regularly as prescribed, even if seizures have stopped.^[14]

Corticosteroids, particularly dexamethasone, are frequently used to reduce brain swelling (edema) caused by the tumor or treatments. While these drugs can dramatically improve symptoms like headaches and weakness, long-term use can cause side effects including weight gain, mood changes, elevated blood sugar, weakened bones, and increased infection risk. Doctors try to use the lowest effective dose for the shortest time possible.^[14]

Innovative Treatments Being Tested in Clinical Trials

While standard treatments have improved outcomes for many patients with malignant astrocytoma, these tumors remain very difficult to cure, especially glioblastomas. This has led researchers worldwide to investigate new and innovative approaches in clinical trials. These studies test whether experimental drugs, new combinations of existing treatments, or entirely novel therapies might work better than current options.^[12]

Understanding Clinical Trial Phases

Clinical trials are conducted in phases, each with a specific purpose. Phase I trials test a new treatment in a small group of people to evaluate its safety, determine safe dosage ranges, and identify side effects. Phase II trials involve more participants and aim to see if the treatment has an effect on the tumor and to further assess safety. Phase III trials compare the new treatment to the current standard treatment in large groups of patients to determine which works better. Only after a treatment successfully passes through all these phases can it be approved for general use.^[12]

Targeted Therapy and Molecular Approaches

Scientists have discovered that certain genetic and molecular changes occur in astrocytoma cells, and treatments can now be designed to specifically target these abnormalities. One important example involves tumors with BRAF gene mutations, particularly in pediatric and young adult patients. Drugs called BRAF inhibitors (such as dabrafenib) and MEK inhibitors (such as trametinib) have been tested in clinical trials and recently approved for certain types of astrocytoma with BRAF alterations. These drugs work by blocking specific proteins that help cancer cells grow and divide.^[14]

Another area of investigation involves drugs that target IDH mutations. Tumors with IDH mutations produce an abnormal protein that disrupts normal cell function. Researchers are testing IDH inhibitors—drugs designed to block this abnormal protein—in clinical trials to see if they can slow tumor growth or improve survival in patients whose tumors have this genetic change.^[15]

Clinical trials are also exploring drugs that interfere with tumor blood vessel formation, a process called angiogenesis. One such drug, bevacizumab, blocks a protein called VEGF that tumors use to grow new blood vessels. While bevacizumab is approved for recurrent glioblastoma, trials continue to examine whether it might also help when given earlier or in combination with other treatments.^[14]

Immunotherapy Approaches

Immunotherapy works by helping the body’s own immune system recognize and attack cancer cells. Several types of immunotherapy are being studied for malignant astrocytoma. One approach involves checkpoint inhibitors—drugs that release the brakes on immune cells, allowing them to fight cancer more effectively. These include drugs like pembrolizumab and nivolumab, which have shown success in other cancers. Trials are testing whether they work in brain tumors, either alone or combined with other treatments.^[14]

Vaccine therapies are another form of immunotherapy being investigated. These vaccines are designed to train the immune system to recognize specific proteins found on astrocytoma cells. One example is the peptide vaccine approach targeting tumor-specific markers. Early-phase trials have tested various vaccine formulations, though more research is needed to determine their effectiveness.^[14]

CAR T-cell therapy is a highly personalized immunotherapy where a patient’s own immune cells (T cells) are collected, genetically modified in a laboratory to attack cancer cells, and then infused back into the patient. While CAR T-cell therapy has been successful in treating certain blood cancers, adapting it for brain tumors presents unique challenges. Researchers are working on ways to help these modified cells reach the brain and attack astrocytoma cells effectively. Several early-phase trials are testing this approach.^[14]

Tumor Treating Fields (TTFields)

A relatively newer treatment approach approved for glioblastoma involves tumor treating fields or TTFields. This therapy uses low-intensity electrical fields delivered through adhesive patches placed on the scalp. These fields disrupt cancer cell division without significantly affecting normal cells. Patients wear a portable device connected to the patches for at least 18 hours each day while continuing with chemotherapy. Clinical trials have shown that adding TTFields to standard chemotherapy can improve survival in some patients with newly diagnosed glioblastoma. While this treatment is already approved in some countries including the United States, ongoing trials continue to refine its use.^[14]

Viral Therapy

Another innovative approach being tested is oncolytic viral therapy, which uses specially engineered viruses that can infect and kill cancer cells while leaving normal cells unharmed. These viruses can also stimulate an immune response against the tumor. One example being studied in clinical trials is a modified herpes virus that is injected directly into the tumor during surgery. Early results have been promising, and larger trials are underway to better understand this treatment’s potential.^[14]

Trial Locations and Eligibility

Clinical trials for astrocytoma are conducted at major cancer centers worldwide, including institutions in the United States, Europe, and other regions. Patients interested in clinical trials can discuss options with their medical team or search for trials through registries and databases designed for this purpose. Eligibility for trials depends on factors such as tumor type and grade, previous treatments, genetic features of the tumor, overall health, and age.^[12]

Most common treatment methods

• Surgery
  • Brain surgeon works to remove as much tumor as possible while preserving brain function
  • May involve advanced techniques like functional MRI mapping and fluorescent guidance using 5-ALA
  • Goal is to achieve maximal safe resection, ideally removing more than 98% of visible tumor
  • In difficult locations, biopsy may be performed instead of extensive tumor removal
• Radiation Therapy
  • Uses high-energy X-rays to destroy remaining cancer cells after surgery
  • Typically given five days per week for about six weeks
  • Side effects include fatigue, hair loss, scalp irritation, and possible cognitive changes
  • Modern techniques like IMRT allow precise targeting of tumor areas
• Chemotherapy
  • Temozolomide is the most commonly used drug, taken as a pill
  • Given during radiation and continued for several months in cycles afterward
  • Side effects include nausea, fatigue, constipation, and lowered blood counts
  • Alternative regimens like PCV may be used for tumors with specific genetic features
• Targeted Therapy
  • BRAF and MEK inhibitors for tumors with BRAF mutations
  • IDH inhibitors being tested for tumors with IDH mutations
  • Bevacizumab targeting tumor blood vessel formation
• Immunotherapy
  • Checkpoint inhibitors like pembrolizumab and nivolumab
  • Vaccine therapies designed to train immune system against tumor cells
  • CAR T-cell therapy using genetically modified patient immune cells
• Tumor Treating Fields (TTFields)
  • Uses low-intensity electrical fields through scalp patches
  • Worn at least 18 hours daily while continuing chemotherapy
  • Approved for glioblastoma in some countries including the United States
• Supportive Medications
  • Anticonvulsants like levetiracetam to prevent or control seizures
  • Corticosteroids such as dexamethasone to reduce brain swelling